DrugPatentWatch Database Preview
Drugs in Development Information for Pixantrone
» See Plans and Pricing
What is the drug development status for Pixantrone?
Pixantrone is an investigational drug.
There have been 18 clinical trials for Pixantrone.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Non-Hodgkin, and Lymphoma, B-Cell. The leading clinical trial sponsors are CTI BioPharma, Theradex, and Johannes Gutenberg University Mainz.
Summary for Pixantrone
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2,400 |
| WIPO Patent Applications | 1,685 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2007-08-01) |
| Vendors | 49 |
Recent Clinical Trials for Pixantrone
| Title | Sponsor | Phase |
|---|---|---|
| Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma | The Lymphoma Academic Research Organisation | Phase 2 |
| Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer | CTI BioPharma | Phase 1 |
| Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study | University of Aarhus | Phase 1/Phase 2 |
Clinical Trial Summary for Pixantrone
Top disease conditions for Pixantrone
Top clinical trial sponsors for Pixantrone
US Patents for Pixantrone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
